Business Context and Reporting Period
Company: Biorestorative Therapies, Inc. (BRTX)
Filing Type: Form 8-K (Current Report)
Date: April 14, 2023
Event: Entry into a Material Agreement (Capital On Demand Sales Agreement).
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It details a potential equity financing arrangement.
- Maximum Offering Size: Up to $3.7 million in aggregate offering price.
- Security Type: Common Stock, $0.0001 par value.
- Agent Commission: 3.0% of the gross sales price of shares sold.
- Trading Venue: Nasdaq Capital Market.
Material Changes
On April 14, 2023, the Company entered into a Sales Agreement with JonesTrading Institutional Services LLC. This agreement allows the Company to sell shares through an "at-the-market" offering. The Company is not obligated to sell any shares under this agreement.
Guidance, Outlook, and Risks
Management Commentary: The Company may offer and sell shares from time to time based on its instructions, including price, time, or size limits. The Agent will use commercially reasonable efforts to sell shares consistent with normal trading practices.
Terms and Termination: The Sales Agreement may be terminated by either the Agent or the Company at any time upon notice to the other party.
Risks/Contingencies: The filing does not explicitly list new risks beyond the standard terms of an at-the-market offering. The issuance is subject to the Company's effective Registration Statement on Form S-3 (No. 333-269631).
Investor Verification Checklist
- Verify the current share price and potential dilution impact of selling up to $3.7 million in shares.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific pricing parameters or volume limits.
- Confirm the status of the underlying Form S-3 Registration Statement (No. 333-269631).
- Monitor future filings for actual sales volumes and proceeds generated under this agreement.